International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWG for Myelofibrosis Research and Treatment (IWG-MRT)

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM

Practical management of classical myeloproliferative disorder patients: a clinician's guide.

Mesa RA

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A

Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.

Tefferi A, Dingli D, Li CY, Mesa RA

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A

Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.

Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A

Tipifarnib: farnesyl transferase inhibition at a crossroads.

Mesa RA